<Summary id="CDR0000258000" LegacyPDQID="1162" ReplacementFor="CDR0000062694"><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Patients</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Childhood acute myeloid leukemia and other myeloid malignancies treatment may include chemotherapy, radiation therapy, and targeted therapy. Learn more about AML and myelodysplastic/myeloproliferative diseases in this expert-reviewed summary.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/leukemia/patient/child-aml-treatment-pdq">Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies (PDQ®): Treatment</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/leukemia/hp/child-aml-treatment-pdq">Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies (PDQ®): Treatment</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028557">PDQ Pediatric Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000775587">childhood acute myeloid leukemia</TermRef></MainTopics><MainTopics><TermRef ref="CDR0000039928">childhood acute promyelocytic leukemia (M3)</TermRef></MainTopics><MainTopics><TermRef ref="CDR0000559318">childhood myelodysplastic syndromes</TermRef></MainTopics><MainTopics><TermRef ref="CDR0000038439">juvenile myelomonocytic leukemia</TermRef></MainTopics><MainTopics><TermRef ref="CDR0000286994">childhood chronic myelogenous leukemia</TermRef></MainTopics><SummaryAbstract><Para id="_361">This PDQ cancer information summary has current information about the treatment of childhood acute myeloid leukemia and other myeloid malignancies. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.</Para><Para id="_362">Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Date Last Modified") is the date of the most recent change. The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the PDQ Pediatric Treatment Editorial Board.</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>Childhood acute myeloid leukemia</SummaryKeyWord><SummaryKeyWord>Childhood acute promyelocytic leukemia (M3)</SummaryKeyWord><SummaryKeyWord>Childhood chronic myelogenous leukemia</SummaryKeyWord><SummaryKeyWord>Childhood myelodysplastic syndromes</SummaryKeyWord><SummaryKeyWord>Juvenile myelomonocytic leukemia</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version</SummaryTitle><AltTitle TitleType="Browser">Childhood Acute Myeloid Leukemia Treatment</AltTitle><AltTitle TitleType="CancerTypeHomePage">Childhood Acute Myeloid Leukemia Treatment</AltTitle><SummarySection id="_1"><Title>General Information About Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies</Title><SummarySection id="_326"><SectMetaData><SectionType>Cancer description</SectionType><SectionType>Organ description</SectionType></SectMetaData><KeyPoint id="_327">Childhood acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes a large number of abnormal blood cells.</KeyPoint><Para id="_328">Childhood <GlossaryTermRef href="CDR0000046347" dictionary="Cancer.gov" audience="Patient">acute myeloid leukemia</GlossaryTermRef> (AML) is a <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef> of the <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef>. AML is also called acute myelogenous leukemia and acute nonlymphocytic leukemia. Cancers that are <GlossaryTermRef href="CDR0000045585" dictionary="Cancer.gov" audience="Patient">acute</GlossaryTermRef> usually get worse quickly if they are not treated. Cancers that are <GlossaryTermRef href="CDR0000045641" dictionary="Cancer.gov" audience="Patient">chronic</GlossaryTermRef> usually get worse slowly.</Para><MediaLink ref="CDR0000755927" type="image/jpeg" alt="Anatomy of the bone; drawing shows spongy bone, red marrow, and yellow marrow. A cross section of the bone shows compact bone and blood vessels in the bone marrow. Also shown are red blood cells, white blood cells, platelets, and a blood stem cell." language="en" placement="image-center" id="_332"><Caption language="en">Anatomy of the bone. The bone is made up of compact bone, spongy bone, and bone marrow. Compact bone makes up the outer layer of the bone. Spongy bone is found mostly at the ends of bones and contains red marrow. Bone marrow is found in the center of most bones and has many blood vessels. There are two types of bone marrow: red and yellow. Red marrow contains blood stem cells that can become red blood cells, white blood cells, or platelets. Yellow marrow is made mostly of fat.</Caption></MediaLink><Para id="_437">This summary is about the treatment of childhood AML,  <GlossaryTermRef href="CDR0000792763" dictionary="Cancer.gov" audience="Patient">transient abnormal myelopoiesis</GlossaryTermRef>, childhood <GlossaryTermRef href="CDR0000444957" dictionary="Cancer.gov" audience="Patient">acute promyelocytic leukemia</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045048" dictionary="Cancer.gov" audience="Patient">juvenile myelomonocytic leukemia</GlossaryTermRef>, childhood <GlossaryTermRef href="CDR0000044901" dictionary="Cancer.gov" audience="Patient">chronic myelogenous leukemia</GlossaryTermRef>, and childhood <GlossaryTermRef href="CDR0000045266" dictionary="Cancer.gov" audience="Patient">myelodysplastic syndromes</GlossaryTermRef>.
		  For information about the treatment of childhood <GlossaryTermRef href="CDR0000045586" dictionary="Cancer.gov" audience="Patient">acute lymphoblastic leukemia</GlossaryTermRef>, see <SummaryRef href="CDR0000258001" url="/types/leukemia/patient/child-all-treatment-pdq">Childhood Acute Lymphoblastic Leukemia Treatment</SummaryRef>.</Para></SummarySection><SummarySection id="_218"><SectMetaData><SectionType>Cancer description</SectionType></SectMetaData><KeyPoint id="_219">Leukemia and other diseases of the blood and bone marrow may affect red blood cells, white blood cells, and platelets.</KeyPoint><Para id="_220">In healthy children,
		  the bone marrow makes <GlossaryTermRef href="CDR0000765906" dictionary="Cancer.gov" audience="Patient">blood stem cells</GlossaryTermRef> (immature <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef>) that become mature blood cells over time. A blood stem cell may become a <GlossaryTermRef href="CDR0000046279" dictionary="Cancer.gov" audience="Patient">myeloid</GlossaryTermRef> <GlossaryTermRef href="CDR0000046598" dictionary="Cancer.gov" audience="Patient">stem cell</GlossaryTermRef> or a <GlossaryTermRef href="CDR0000046298" dictionary="Cancer.gov" audience="Patient">lymphoid</GlossaryTermRef> stem cell. A lymphoid stem cell becomes a type of <GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">white blood cell</GlossaryTermRef>.  </Para><Para id="_329">A myeloid stem cell becomes one of  three types of mature blood cells: </Para><ItemizedList id="_221" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000046124" dictionary="Cancer.gov" audience="Patient">Red blood cells</GlossaryTermRef> that carry <GlossaryTermRef href="CDR0000538149" dictionary="Cancer.gov" audience="Patient">oxygen</GlossaryTermRef> and other  substances to all
			 <GlossaryTermRef href="CDR0000046683" dictionary="Cancer.gov" audience="Patient">tissues</GlossaryTermRef> of the body.</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000046374" dictionary="Cancer.gov" audience="Patient">Granulocytes</GlossaryTermRef>, which are white blood cells that help fight <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infection</GlossaryTermRef> and disease.</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000045840" dictionary="Cancer.gov" audience="Patient">Platelets</GlossaryTermRef> that form    <GlossaryTermRef href="CDR0000476017" dictionary="Cancer.gov" audience="Patient">blood clots</GlossaryTermRef> to
			 stop bleeding.</ListItem></ItemizedList><MediaLink ref="CDR0000526538" type="image/jpeg" alt="Blood cell development; drawing shows the steps a blood stem cell goes through to become a red blood cell, platelet, or white blood cell. A myeloid stem cell becomes a red blood cell, a platelet, or a myeloblast, which then becomes a granulocyte (the types of granulocytes are eosinophils, basophils, and neutrophils). A lymphoid stem cell becomes a lymphoblast and then becomes a B-lymphocyte, T-lymphocyte, or natural killer cell." language="en" placement="image-center" id="_266"><Caption language="en">Blood cell development. A blood stem cell goes through several steps to become a red blood cell, platelet, or white blood cell. </Caption></MediaLink><Para id="_330">In AML, the myeloid stem cells usually become a type of immature white blood cell called <GlossaryTermRef href="CDR0000742483" dictionary="Cancer.gov" audience="Patient">myeloblasts</GlossaryTermRef>  (or myeloid <GlossaryTermRef href="CDR0000046503" dictionary="Cancer.gov" audience="Patient">blasts</GlossaryTermRef>). The myeloblasts, or <GlossaryTermRef href="CDR0000045343" dictionary="Cancer.gov" audience="Patient">leukemia</GlossaryTermRef> cells, in AML are <GlossaryTermRef href="CDR0000044636" dictionary="Cancer.gov" audience="Patient">abnormal</GlossaryTermRef> and do not become healthy white blood cells. The leukemia cells can build up in the blood and bone marrow so there is less room for healthy white blood cells, red blood cells, and platelets. This may lead to infection, <GlossaryTermRef href="CDR0000045360" dictionary="Cancer.gov" audience="Patient">anemia</GlossaryTermRef>, or easy bleeding.</Para><Para id="_373"> The leukemia cells can spread outside the blood to other parts of the body, including the <GlossaryTermRef href="CDR0000046481" dictionary="Cancer.gov" audience="Patient">central nervous system</GlossaryTermRef> (brain and <GlossaryTermRef href="CDR0000340937" dictionary="Cancer.gov" audience="Patient">spinal cord</GlossaryTermRef>), skin, and <GlossaryTermRef href="CDR0000481753" dictionary="Cancer.gov" audience="Patient">gums</GlossaryTermRef>. Sometimes leukemia cells form a <GlossaryTermRef href="CDR0000045301" dictionary="Cancer.gov" audience="Patient">solid tumor</GlossaryTermRef> called a <GlossaryTermRef href="CDR0000806037" dictionary="Cancer.gov" audience="Patient">myeloid sarcoma</GlossaryTermRef>. Myeloid sarcoma is also called granulocytic sarcoma
		  or chloroma.</Para></SummarySection><SummarySection id="_222"><SectMetaData><SectionType>Cancer description</SectionType></SectMetaData><KeyPoint id="_223">Other myeloid diseases can affect the blood and bone marrow.</KeyPoint><SummarySection id="_374"><KeyPoint id="_375">Transient abnormal myelopoiesis (TAM)</KeyPoint><Para id="_376"><GlossaryTermRef href="CDR0000792758" dictionary="Cancer.gov" audience="Patient">TAM</GlossaryTermRef> is a <GlossaryTermRef href="CDR0000407758" dictionary="Cancer.gov" audience="Patient">disorder</GlossaryTermRef> of the bone marrow that can develop in newborns who have <GlossaryTermRef href="CDR0000045488" dictionary="Cancer.gov" audience="Patient">Down syndrome</GlossaryTermRef>. TAM usually goes away on its own within the first 3 months of life. Infants who have TAM have an increased chance of developing AML before the age of 3 years. TAM is also called transient myeloproliferative disorder or transient leukemia. </Para></SummarySection><SummarySection id="_378"><KeyPoint id="_379">Acute promyelocytic leukemia (APL)</KeyPoint><Para id="_380"><GlossaryTermRef href="CDR0000444957" dictionary="Cancer.gov" audience="Patient">APL</GlossaryTermRef> is a subtype of AML. In APL, some <GlossaryTermRef href="CDR0000045693" dictionary="Cancer.gov" audience="Patient">genes</GlossaryTermRef> on <GlossaryTermRef href="CDR0000046470" dictionary="Cancer.gov" audience="Patient">chromosome</GlossaryTermRef> 15 switch places with some genes on <GlossaryTermRef href="CDR0000737156" dictionary="Cancer.gov" audience="Patient">chromosome 17</GlossaryTermRef> and an abnormal gene called <GeneName>PML-RARA</GeneName> is made. The <GeneName>PML-RARA</GeneName> gene sends a message that stops promyelocytes (a type of white blood cell) from maturing. The promyelocytes (leukemia cells) can build up in the blood and bone marrow so there is less room for healthy white blood cells, red blood cells, and platelets. Problems with   severe bleeding and blood clots may also occur. This is a serious health problem that needs treatment as soon as possible.</Para></SummarySection><SummarySection id="_227"><KeyPoint id="_228">Juvenile myelomonocytic leukemia (JMML)</KeyPoint><Para id="_229"><GlossaryTermRef href="CDR0000045048" dictionary="Cancer.gov" audience="Patient">JMML</GlossaryTermRef> is a rare <GlossaryTermRef href="CDR0000728326" dictionary="Cancer.gov" audience="Patient">childhood cancer</GlossaryTermRef> that is most common in children around the age of 2 years and is more common in boys. In JMML, too many myeloid blood stem cells    become myelocytes and <GlossaryTermRef href="CDR0000046282" dictionary="Cancer.gov" audience="Patient">monocytes</GlossaryTermRef> (two types of white blood cells). Some of these myeloid blood stem cells never become mature white blood cells. These immature cells, called blasts, are unable to do their usual work. Over time, the  myelocytes, monocytes, and blasts crowd out the healthy white blood cells, red blood cells, and platelets in the bone marrow. When this happens, infection, anemia, or easy bleeding may occur.</Para></SummarySection><SummarySection id="_224"><KeyPoint id="_225">Chronic myelogenous leukemia (CML)</KeyPoint><Para id="_226"><GlossaryTermRef href="CDR0000044382" dictionary="Cancer.gov" audience="Patient">CML</GlossaryTermRef> often begins in an early myeloid blood cell when a certain gene change occurs. A section of genes, that includes the <GeneName>ABL</GeneName> gene, on chromosome 9 changes place with a section of genes on chromosome 22, which has the <GeneName>BCR</GeneName> gene. This makes a very short chromosome 22 (called the <GlossaryTermRef href="CDR0000044179" dictionary="Cancer.gov" audience="Patient">Philadelphia chromosome</GlossaryTermRef>) and a very long chromosome 9. An abnormal <GeneName><GlossaryTermRef href="CDR0000561237" dictionary="Cancer.gov" audience="Patient">BCR-ABL</GlossaryTermRef></GeneName> gene is formed on chromosome 22. The <GeneName>BCR-ABL</GeneName> gene tells the blood cells to make too much of a <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">protein</GlossaryTermRef> called tyrosine kinase. Tyrosine kinase causes too many abnormal white blood cells (leukemia cells) to be made in the bone marrow. The leukemia cells can build up in the blood and bone marrow so there is less room for healthy white blood cells, red blood cells, and platelets. This can lead to infection, anemia, or easy bleeding. CML is rare in children.<MediaLink ref="CDR0000533336" type="image/jpeg" alt="Philadelphia chromosome; three-panel drawing shows a piece of chromosome 9 and a piece of chromosome 22 breaking off and trading places, creating a changed chromosome 22 called the Philadelphia chromosome. In the left panel, the drawing shows a normal chromosome 9 with the ABL1 gene and a normal chromosome 22 with the BCR gene. In the center panel, the drawing shows part of the ABL1 gene breaking off from chromosome 9 and a piece of chromosome 22 breaking off, below the BCR gene. In the right panel, the drawing shows chromosome 9 with the piece from chromosome 22 attached. It also shows a shortened version of chromosome 22 with the piece from chromosome 9 containing part of the ABL1 gene attached. The ABL1 gene joins to the BCR gene on chromosome 22 to form the BCR::ABL1 fusion gene. The changed chromosome 22 with the BCR::ABL1 fusion gene on it is called the Philadelphia chromosome." language="en" placement="image-center" id="_423"><Caption language="en">The Philadelphia (Ph) chromosome is an abnormal chromosome that is made when pieces of chromosomes 9 and 22 break off and trade places. The <GeneName>ABL1</GeneName> gene from chromosome 9 joins to the <GeneName>BCR</GeneName> gene on chromosome 22 to form the <GeneName>BCR</GeneName>::<GeneName>ABL1</GeneName> fusion gene. The changed chromosome 22 with the fusion gene on it is called the Ph chromosome. </Caption></MediaLink></Para></SummarySection><SummarySection id="_233"><KeyPoint id="_234">Myelodysplastic syndromes (MDS)</KeyPoint><Para id="_235"><GlossaryTermRef href="CDR0000045266" dictionary="Cancer.gov" audience="Patient">MDS</GlossaryTermRef> occur less often in children than in adults. In MDS, the bone marrow makes too few red blood cells, white blood cells, and platelets.  These blood cells may not mature and enter the blood. The type of MDS depends on the type of blood cell that is affected.</Para><Para id="_415">The treatment for MDS depends on how low the numbers of red blood cells, white blood cells, or platelets are. Over time, MDS may become AML.</Para></SummarySection></SummarySection><SummarySection id="_316"><KeyPoint id="_317">AML or MDS may occur after treatment with certain chemotherapy drugs and/or radiation therapy. </KeyPoint><Para id="_318">Cancer treatment with certain <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef> and/or <GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">radiation therapy</GlossaryTermRef> may cause <GlossaryTermRef href="CDR0000790623" dictionary="Cancer.gov" audience="Patient">therapy-related AML</GlossaryTermRef> (t-AML) or <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef>-related MDS (t-MDS).  The risk of these therapy-related myeloid diseases depends on the total <GlossaryTermRef href="CDR0000044664" dictionary="Cancer.gov" audience="Patient">dose</GlossaryTermRef> of the chemotherapy drugs used and the <GlossaryTermRef href="CDR0000045072" dictionary="Cancer.gov" audience="Patient">radiation</GlossaryTermRef> dose and <GlossaryTermRef href="CDR0000044741" dictionary="Cancer.gov" audience="Patient">treatment field</GlossaryTermRef>. Some patients also have an <GlossaryTermRef href="CDR0000045098" dictionary="Cancer.gov" audience="Patient">inherited</GlossaryTermRef> risk for  t-AML and t-MDS.  These therapy-related diseases usually occur within 7 years after treatment, but are rare in children.</Para></SummarySection><SummarySection id="_15"><SectMetaData><SectionType>Risk factors</SectionType></SectMetaData><KeyPoint id="_16">The risk factors for childhood acute myeloid leukemia and other myeloid malignancies are similar.</KeyPoint><Para id="_17">Anything that increases your risk of getting a disease is called a <GlossaryTermRef href="CDR0000045873" dictionary="Cancer.gov" audience="Patient">risk factor</GlossaryTermRef>. Having a risk factor does not mean that you will get cancer; not having risk factors doesn’t mean that you will not get cancer. Talk with your child’s doctor if you think your child may be at risk. These and other factors may increase the risk of childhood AML, APL, JMML, CML, and MDS:</Para><ItemizedList id="_18" Style="bullet"> 
		  <ListItem>Having a brother or sister, especially a twin, with leukemia.</ListItem><ListItem>Having a <GlossaryTermRef href="CDR0000642021" dictionary="Cancer.gov" audience="Patient">personal history</GlossaryTermRef> of bone marrow failure.</ListItem> 
		  <ListItem>Having a personal history of MDS.</ListItem><ListItem>Past treatment with chemotherapy or radiation therapy.</ListItem> 
		  <ListItem>Being exposed to <GlossaryTermRef href="CDR0000430698" dictionary="Cancer.gov" audience="Patient">ionizing radiation</GlossaryTermRef> or <GlossaryTermRef href="CDR0000643008" dictionary="Cancer.gov" audience="Patient">chemicals</GlossaryTermRef> such as <GlossaryTermRef href="CDR0000270734" dictionary="Cancer.gov" audience="Patient">benzene</GlossaryTermRef>.</ListItem><ListItem>Having certain <GlossaryTermRef href="CDR0000045090" dictionary="Cancer.gov" audience="Patient">syndromes</GlossaryTermRef> or inherited disorders, such as:<ItemizedList id="_306" Style="dash">
     <ListItem>Down syndrome.</ListItem><ListItem>Aplastic anemia.</ListItem><ListItem><GlossaryTermRef href="CDR0000045499" dictionary="Cancer.gov" audience="Patient">Fanconi anemia</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045096" dictionary="Cancer.gov" audience="Patient">Neurofibromatosis type 1</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000683528" dictionary="Cancer.gov" audience="Patient">Noonan syndrome</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000644776" dictionary="Cancer.gov" audience="Patient">Shwachman-Diamond syndrome</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000666665" dictionary="Cancer.gov" audience="Patient">Diamond-Blackfan anemia</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000798927" dictionary="Cancer.gov" audience="Patient">Dyskeratosis congenita</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046322" dictionary="Cancer.gov" audience="Patient">Li-Fraumeni syndrome</GlossaryTermRef>.</ListItem></ItemizedList></ListItem> 
		</ItemizedList></SummarySection><SummarySection id="_19"><SectMetaData><SectionType>Symptoms</SectionType></SectMetaData><KeyPoint id="_20">Signs and symptoms of childhood acute myeloid leukemia and other myeloid malignancies include
		  fever, feeling tired, and easy bleeding or bruising.</KeyPoint><Para id="_21">These and other <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> may be caused by childhood AML, APL, JMML, CML, or MDS or by other <GlossaryTermRef href="CDR0000651193" dictionary="Cancer.gov" audience="Patient">conditions</GlossaryTermRef>. Check with a doctor if your child has any of the following:</Para><ItemizedList id="_22" Style="bullet"> 
		  <ListItem><GlossaryTermRef href="CDR0000450108" dictionary="Cancer.gov" audience="Patient">Fever</GlossaryTermRef> with or without an infection.</ListItem><ListItem>Drenching <GlossaryTermRef href="CDR0000454810" dictionary="Cancer.gov" audience="Patient">night sweats</GlossaryTermRef>.</ListItem> 
		  <ListItem>Shortness of breath.</ListItem> 
		  <ListItem>Weakness, feeling tired, or looking pale.</ListItem><ListItem>Easy bruising or bleeding.</ListItem><ListItem><GlossaryTermRef href="CDR0000046236" dictionary="Cancer.gov" audience="Patient">Petechiae</GlossaryTermRef> (flat, pinpoint spots under the skin caused by bleeding).</ListItem><ListItem>Bone or <GlossaryTermRef href="CDR0000458080" dictionary="Cancer.gov" audience="Patient">joint</GlossaryTermRef> pain.</ListItem> 
		  <ListItem>Pain or feeling of fullness below the ribs.</ListItem> 
		  <ListItem>Painless lumps in the neck, underarm, <GlossaryTermRef href="CDR0000046604" dictionary="Cancer.gov" audience="Patient">stomach</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046375" dictionary="Cancer.gov" audience="Patient">groin</GlossaryTermRef>, or other parts of the body. In childhood AML, these lumps, called leukemia cutis,  may be blue or purple.</ListItem><ListItem>Painless lumps that are sometimes  around the eyes. These lumps, called myeloid sarcomas, are sometimes seen in childhood AML and may be blue-green.</ListItem><ListItem>An <GlossaryTermRef href="CDR0000462675" dictionary="Cancer.gov" audience="Patient">eczema</GlossaryTermRef>-like skin rash.</ListItem> 
		   
		   
		<ListItem>Loss of <GlossaryTermRef href="CDR0000454699" dictionary="Cancer.gov" audience="Patient">appetite</GlossaryTermRef> or weight loss.</ListItem><ListItem>Headache, trouble seeing, or <GlossaryTermRef href="CDR0000450096" dictionary="Cancer.gov" audience="Patient">confusion</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_238">The signs and symptoms of TAM may include the following:</Para><ItemizedList id="_239" Style="bullet"><ListItem>Swelling all over the body.</ListItem><ListItem>Shortness of breath.</ListItem><ListItem>Trouble breathing.</ListItem><ListItem>Increased <GlossaryTermRef href="CDR0000748353" dictionary="Cancer.gov" audience="Patient">heart rate</GlossaryTermRef>.</ListItem><ListItem>Weakness, feeling tired, or looking pale.</ListItem><ListItem>Easy bleeding or bruising.</ListItem><ListItem>Petechiae (flat, pinpoint spots under the skin caused by bleeding).</ListItem><ListItem>Pain below the ribs.</ListItem><ListItem>Skin rash.</ListItem><ListItem>  
    <GlossaryTermRef href="CDR0000046328" dictionary="Cancer.gov" audience="Patient">Jaundice</GlossaryTermRef> (yellowing of the skin and whites of the eyes).</ListItem> 
		  </ItemizedList><Para id="_377">Sometimes TAM does not cause any symptoms at all and is <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosed</GlossaryTermRef> after a routine <GlossaryTermRef href="CDR0000688783" dictionary="Cancer.gov" audience="Patient">blood test</GlossaryTermRef>. </Para></SummarySection><SummarySection id="_23"><SectMetaData><SectionType>Diagnostic tests</SectionType></SectMetaData><KeyPoint id="_24">Tests that examine the blood and bone marrow are used to diagnose and find any spread of childhood acute myeloid leukemia and other myeloid malignancies.</KeyPoint><Para id="_25">The following tests and procedures may be used:</Para><ItemizedList id="_26" Style="bullet"> 
		  <ListItem><Strong><GlossaryTermRef href="CDR0000270871" dictionary="Cancer.gov" audience="Patient">Physical exam</GlossaryTermRef> and <GlossaryTermRef href="CDR0000798522" dictionary="Cancer.gov" audience="Patient">health history</GlossaryTermRef></Strong>: An exam of the body to check general signs of health, including checking for signs of disease, such as lumps or anything else that seems unusual. A history of the patient’s health habits and past illnesses and treatments will also be taken.
			 </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045107" dictionary="Cancer.gov" audience="Patient">Complete blood count</GlossaryTermRef> (CBC)   with differential</Strong>: A procedure in which a sample of blood is drawn and checked for the following: 
			 <ItemizedList id="_104" Style="dash"> 
			 <ListItem> 
The number of red blood cells and platelets.</ListItem><ListItem>The number and type of white blood cells.</ListItem><ListItem>The portion of the blood sample made up of red blood cells.

</ListItem><ListItem>The amount of <GlossaryTermRef href="CDR0000045108" dictionary="Cancer.gov" audience="Patient">hemoglobin</GlossaryTermRef> (the protein that carries <GlossaryTermRef href="CDR0000538149" dictionary="Cancer.gov" audience="Patient">oxygen</GlossaryTermRef>) in the red blood cells.</ListItem></ItemizedList><MediaLink ref="CDR0000526546" type="image/jpeg" alt="Complete blood count (CBC); left panel shows blood being drawn from a vein on the inside of the elbow using a tube attached to a syringe; right panel shows a laboratory test tube with blood cells separated into layers: plasma, white blood cells, platelets, and red blood cells." language="en" placement="image-center" id="_256"><Caption language="en">Complete blood count (CBC). Blood is collected by inserting a needle into a vein and allowing the blood to flow into a tube. The blood sample is sent to the laboratory and the red blood cells, white blood cells, and platelets are counted.  The CBC is used to test for, diagnose, and monitor many different conditions.</Caption></MediaLink> </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000304687" dictionary="Cancer.gov" audience="Patient">Chest x-ray</GlossaryTermRef></Strong>: An <GlossaryTermRef href="CDR0000045944" dictionary="Cancer.gov" audience="Patient">x-ray</GlossaryTermRef> of the <GlossaryTermRef href="CDR0000257523" dictionary="Cancer.gov" audience="Patient">organs</GlossaryTermRef> and bones inside the chest.  An x-ray is a type of energy beam that can go through the body and onto film, making a picture of areas inside the body.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045164" dictionary="Cancer.gov" audience="Patient">Biopsy</GlossaryTermRef></Strong>: The removal of cells or tissues so they can be viewed under a <GlossaryTermRef href="CDR0000638184" dictionary="Cancer.gov" audience="Patient">microscope</GlossaryTermRef> by a <GlossaryTermRef href="CDR0000046244" dictionary="Cancer.gov" audience="Patient">pathologist</GlossaryTermRef> to check for signs of cancer. Biopsies that may be done include the following:<ItemizedList id="_115" Style="dash"><ListItem><Strong><GlossaryTermRef href="CDR0000046505" dictionary="Cancer.gov" audience="Patient">Bone marrow aspiration</GlossaryTermRef> and <GlossaryTermRef href="CDR0000046506" dictionary="Cancer.gov" audience="Patient">biopsy</GlossaryTermRef></Strong>: The removal of bone marrow and a small piece of bone by inserting a hollow needle into the hipbone or <GlossaryTermRef href="CDR0000549425" dictionary="Cancer.gov" audience="Patient">breastbone</GlossaryTermRef>.<MediaLink ref="CDR0000775458" type="image/jpeg" alt="Bone marrow aspiration and biopsy; drawing shows a child lying face down on a table and a bone marrow needle being inserted into the right hip bone. An inset shows the bone marrow needle being inserted through the skin into the bone marrow of the hip bone." language="en" placement="image-center" id="_363"><Caption language="en">Bone marrow aspiration and biopsy. After a small area of skin is numbed, a bone marrow needle  is inserted into the child’s hip bone.  Samples of blood, bone, and bone marrow are removed for examination under a microscope.</Caption></MediaLink></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046634" dictionary="Cancer.gov" audience="Patient">Tumor</GlossaryTermRef> biopsy for AML</Strong>: The removal of cells or tissues from a lump in the <GlossaryTermRef href="CDR0000046611" dictionary="Cancer.gov" audience="Patient">testicles</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046687" dictionary="Cancer.gov" audience="Patient">ovaries</GlossaryTermRef>, or skin using a needle. This may be done if the doctor suspects the leukemia cells may have formed a solid tumor called a myeloid sarcoma.</ListItem></ItemizedList>  </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000341450" dictionary="Cancer.gov" audience="Patient">Immunophenotyping</GlossaryTermRef></Strong>: A <GlossaryTermRef href="CDR0000046590" dictionary="Cancer.gov" audience="Patient">laboratory test</GlossaryTermRef> that uses <GlossaryTermRef href="CDR0000044918" dictionary="Cancer.gov" audience="Patient">antibodies</GlossaryTermRef> to identify cancer cells based on the types of <GlossaryTermRef href="CDR0000046086" dictionary="Cancer.gov" audience="Patient">antigens</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045776" dictionary="Cancer.gov" audience="Patient">markers</GlossaryTermRef> on the surface of the cells. This test is used to help diagnose specific types of leukemia.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000270737" dictionary="Cancer.gov" audience="Patient">Cytogenetic</GlossaryTermRef> <GlossaryTermRef href="CDR0000390238" dictionary="Cancer.gov" audience="Patient">analysis</GlossaryTermRef></Strong>:  A laboratory test in which the chromosomes of cells in a sample of blood or bone marrow are counted and checked for any changes, such as broken, missing, rearranged, or extra chromosomes. Changes in certain chromosomes may be a sign of cancer. Cytogenetic analysis is used to help diagnose cancer, plan treatment, or find out how well treatment is working.<Para id="_323">The following test is a type of cytogenetic analysis:</Para><ItemizedList id="_324" Style="dash"><ListItem><Strong><GlossaryTermRef href="CDR0000460228" dictionary="Cancer.gov" audience="Patient">FISH</GlossaryTermRef> (fluorescence in situ hybridization)</Strong>: A laboratory test used to look at and count genes or chromosomes in cells and tissues. Pieces of DNA that contain fluorescent dyes are made in the laboratory and added to a sample of a patient’s cells or tissues. When these dyed pieces of <GlossaryTermRef href="CDR0000045671" dictionary="Cancer.gov" audience="Patient">DNA</GlossaryTermRef> attach to certain genes or areas of chromosomes in the sample, they light up when viewed under a fluorescent microscope. The FISH test is used to help diagnose cancer and help plan treatment.</ListItem></ItemizedList></ListItem> 
		  <ListItem><Strong><GlossaryTermRef href="CDR0000766166" dictionary="Cancer.gov" audience="Patient">Molecular testing</GlossaryTermRef></Strong>: A laboratory test to check for certain genes, proteins, or other <GlossaryTermRef href="CDR0000045065" dictionary="Cancer.gov" audience="Patient">molecules</GlossaryTermRef> in a sample of tissue, blood, or bone marrow. Molecular tests also check for certain changes in a gene or chromosome that may cause or affect the chance of developing AML. A molecular test may be used to help plan treatment, find out how well treatment is working, or make a <GlossaryTermRef href="CDR0000045849" dictionary="Cancer.gov" audience="Patient">prognosis</GlossaryTermRef>.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046303" dictionary="Cancer.gov" audience="Patient">Lumbar puncture</GlossaryTermRef></Strong>:  A procedure used to collect a sample of <GlossaryTermRef href="CDR0000046483" dictionary="Cancer.gov" audience="Patient">cerebrospinal fluid</GlossaryTermRef> (CSF) from the <GlossaryTermRef href="CDR0000396787" dictionary="Cancer.gov" audience="Patient">spinal column</GlossaryTermRef>.   This is done by placing a needle between two bones in the <GlossaryTermRef href="CDR0000415914" dictionary="Cancer.gov" audience="Patient">spine</GlossaryTermRef> and into the CSF around the spinal cord and removing a sample of the fluid.  The sample of CSF is checked under a microscope for signs that leukemia cells have spread to the brain and spinal cord. This procedure is also called an LP or spinal tap.<MediaLink ref="CDR0000503953" type="image/jpeg" alt="Lumbar puncture; drawing shows a patient lying in a curled position on a table and a spinal needle (a long, thin needle) being inserted into the lower back. Inset shows a close-up of the spinal needle inserted into the cerebrospinal fluid (CSF) in the lower part of the spinal column." language="en" placement="image-center" id="_268"><Caption language="en">Lumbar puncture. A patient lies in a curled position on a table. After a small area on the lower back is numbed, a spinal needle (a long, thin needle) is inserted into the lower part of the spinal column to remove cerebrospinal fluid (CSF, shown in blue). The fluid may be sent to a laboratory for testing.</Caption></MediaLink></ListItem></ItemizedList></SummarySection><SummarySection id="_27"><SectMetaData><SectionType>Prognostic factors</SectionType></SectMetaData><KeyPoint id="_28">Certain factors affect prognosis (chance
		  of recovery) and treatment options.</KeyPoint><Para id="_105">The prognosis and treatment options for childhood acute myeloid leukemia (AML) depend on the following:</Para><ItemizedList id="_106" Style="bullet"><ListItem>The age of the child when the cancer is diagnosed.</ListItem><ListItem>The race or ethnic group of the child.</ListItem><ListItem>Whether the child is greatly <GlossaryTermRef href="CDR0000304742" dictionary="Cancer.gov" audience="Patient">overweight</GlossaryTermRef>.</ListItem><ListItem> Number of white blood cells in the blood at
		  diagnosis.</ListItem><ListItem>Whether the AML occurred after previous cancer treatment.</ListItem><ListItem>The subtype of AML.</ListItem><ListItem>Whether there are certain chromosome or gene  changes in the leukemia cells.</ListItem><ListItem>Whether the child has Down syndrome. Most children with AML and Down syndrome can be cured of their leukemia when diagnosed before age 4 years.</ListItem><ListItem>Whether the leukemia is in the central nervous system (brain and spinal cord).</ListItem><ListItem>How quickly the leukemia responds to treatment.</ListItem><ListItem>Whether the AML is newly diagnosed (untreated) or has <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurred</GlossaryTermRef> after treatment.</ListItem><ListItem>The length of time since treatment ended, for AML that has recurred.</ListItem></ItemizedList><Para id="_416">The prognosis and treatment options for childhood acute promyelocytic leukemia (APL) depends on the following:</Para><ItemizedList id="_417" Style="bullet"><ListItem> Number of white blood cells in the blood at
		  diagnosis.</ListItem><ListItem>Whether there are certain chromosome or gene  changes in the leukemia cells.</ListItem><ListItem>Whether the APL is newly diagnosed (untreated) or has recurred after treatment.</ListItem></ItemizedList><Para id="_240">The prognosis and treatment options for juvenile myelomonocytic leukemia (JMML) depend on the following:</Para><ItemizedList id="_241" Style="bullet"><ListItem>The age of the child when the cancer is diagnosed.</ListItem><ListItem>The type of gene affected and the number of genes that have changes.</ListItem><ListItem>How many platelets are in the blood after treatment.</ListItem><ListItem>How much hemoglobin is in the blood after treatment.</ListItem><ListItem>Whether the JMML is newly diagnosed (untreated) or has recurred after treatment.</ListItem></ItemizedList><Para id="_242">The prognosis and treatment options for childhood chronic myelogenous leukemia (CML) depend on the following:</Para><ItemizedList id="_418" Style="bullet"><ListItem>How long it has been since the patient was diagnosed.</ListItem><ListItem>How many blast cells are in the blood.</ListItem><ListItem>Whether and how fully the blast cells disappear from the blood and bone marrow after therapy has started.</ListItem><ListItem>Whether the CML is newly diagnosed (untreated) or has recurred after treatment.</ListItem></ItemizedList><Para id="_173">The prognosis and treatment options for myelodysplastic syndromes (MDS) depend on the following:</Para><ItemizedList id="_174" Style="bullet"><ListItem>Whether the MDS was caused by previous cancer treatment.</ListItem><ListItem>How low the numbers of red blood cells, white blood cells, or platelets are.</ListItem><ListItem>Whether the MDS is newly diagnosed (untreated)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            or has recurred after treatment.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_30"><Title>Stages of Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies</Title><SummarySection id="_164"><SectMetaData><SectionType>Classification by stage</SectionType></SectMetaData><KeyPoint id="_165">
     There is no standard staging system for childhood acute myeloid leukemia and other myelogenous malignancies.
    </KeyPoint><Para id="_141">The extent or spread of cancer is usually described as <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stages</GlossaryTermRef>.  Instead of stages, treatment is based on one or more of the following:  </Para><ItemizedList id="_358" Style="bullet"><ListItem>The type of disease or the subtype of AML.</ListItem><ListItem>Whether leukemia has spread outside the blood and <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef>.</ListItem><ListItem>Whether the disease is newly <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosed</GlossaryTermRef>, in <GlossaryTermRef href="CDR0000045867" dictionary="Cancer.gov" audience="Patient">remission</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurrent</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_128"><Strong>Newly diagnosed childhood AML</Strong></Para><Para id="_129">Newly diagnosed childhood AML is cancer that has not been treated except to relieve signs and <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> such as <GlossaryTermRef href="CDR0000450108" dictionary="Cancer.gov" audience="Patient">fever</GlossaryTermRef>, bleeding, or pain, and has one of the following:</Para><ItemizedList id="_130" Style="bullet"><ListItem>More than 20% of the cells in the bone marrow are <GlossaryTermRef href="CDR0000046503" dictionary="Cancer.gov" audience="Patient">blasts</GlossaryTermRef> (leukemia cells).<Para id="_252"><Emphasis>or</Emphasis></Para></ListItem><ListItem>Less than 20% of the cells in the bone marrow are blasts and there is a certain change in the <GlossaryTermRef href="CDR0000046470" dictionary="Cancer.gov" audience="Patient">chromosome</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_131"><Strong>Childhood AML in remission</Strong></Para><Para id="_132">In childhood AML in remission, the disease has been treated and the following are found:</Para><ItemizedList id="_133" Style="bullet"><ListItem>The <GlossaryTermRef href="CDR0000045107" dictionary="Cancer.gov" audience="Patient">complete blood count</GlossaryTermRef> is  almost normal.</ListItem><ListItem>Less than 5% of the cells in the bone marrow are blasts (leukemia cells).</ListItem><ListItem>There are no signs or symptoms of leukemia in the brain, spinal cord, or other parts of the body.</ListItem></ItemizedList></SummarySection><SummarySection id="_419"><KeyPoint id="_420">Sometimes childhood acute myeloid leukemia and other myeloid malignancies do not respond to treatment or come back after treatment.</KeyPoint><Para id="_422"><GlossaryTermRef href="CDR0000045863" dictionary="Cancer.gov" audience="Patient">Refractory</GlossaryTermRef> leukemia is  cancer that does not respond to treatment.</Para><Para id="_421"><GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">Recurrent</GlossaryTermRef> leukemia is cancer that has recurred (come back) after it has been treated. The cancer may come back in the blood and bone marrow or in other
		parts of the body, such as the <GlossaryTermRef href="CDR0000046481" dictionary="Cancer.gov" audience="Patient">central nervous system</GlossaryTermRef> (brain and spinal cord).</Para></SummarySection></SummarySection><SummarySection id="_36"><Title>Treatment Option Overview</Title><SummarySection id="_37"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_38">There are different types of treatment for children with acute myeloid leukemia and other myeloid malignancies. </KeyPoint><Para id="_39">Different types of treatment are available for children with <GlossaryTermRef href="CDR0000044363" dictionary="Cancer.gov" audience="Patient">acute myeloid leukemia</GlossaryTermRef> (AML), <GlossaryTermRef href="CDR0000792763" dictionary="Cancer.gov" audience="Patient">transient abnormal myelopoiesis</GlossaryTermRef> (TAM), <GlossaryTermRef href="CDR0000522912" dictionary="Cancer.gov" audience="Patient">acute promyelocytic leukemia</GlossaryTermRef> (APL), <GlossaryTermRef href="CDR0000450126" dictionary="Cancer.gov" audience="Patient">juvenile myelomonocytic leukemia</GlossaryTermRef> (JMML), <GlossaryTermRef href="CDR0000044382" dictionary="Cancer.gov" audience="Patient">chronic myelogenous leukemia</GlossaryTermRef> (CML), and <GlossaryTermRef href="CDR0000045266" dictionary="Cancer.gov" audience="Patient">myelodysplastic syndromes</GlossaryTermRef> (MDS). Some treatments are <GlossaryTermRef href="CDR0000044930" dictionary="Cancer.gov" audience="Patient">standard</GlossaryTermRef> (the currently used treatment),
		  and some are being tested in <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical
		  trials</GlossaryTermRef>. A treatment clinical trial is a <GlossaryTermRef href="CDR0000651211" dictionary="Cancer.gov" audience="Patient">research
		  study</GlossaryTermRef> meant to help improve current treatments or obtain information on new
		  treatments for patients with <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>. When clinical trials show that a new
		  treatment is better than the standard
		  treatment, the new treatment may become the standard treatment.</Para><Para id="_40">Because AML and other <GlossaryTermRef href="CDR0000046279" dictionary="Cancer.gov" audience="Patient">myeloid</GlossaryTermRef> <GlossaryTermRef href="CDR0000407758" dictionary="Cancer.gov" audience="Patient">disorders</GlossaryTermRef> are rare in children, taking part in a clinical trial
		  should be considered.       Some clinical trials are open only to patients who have not yet started treatment. </Para></SummarySection><SummarySection id="_41"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_42">Treatment is planned by a team of health care providers who are experts in treating childhood
		  leukemia and other diseases of the blood.</KeyPoint><Para id="_43">Treatment will be overseen by a
		  <GlossaryTermRef href="CDR0000693555" dictionary="Cancer.gov" audience="Patient">pediatric oncologist</GlossaryTermRef>, a doctor who specializes
		  in treating children with cancer. The pediatric oncologist works with
		  other <GlossaryTermRef href="CDR0000650566" dictionary="Cancer.gov" audience="Patient">health care providers</GlossaryTermRef> who are experts in treating children
		  with <GlossaryTermRef href="CDR0000045343" dictionary="Cancer.gov" audience="Patient">leukemia</GlossaryTermRef> and who specialize in certain areas of <GlossaryTermRef href="CDR0000482419" dictionary="Cancer.gov" audience="Patient">medicine</GlossaryTermRef>. These may
		  include the following <GlossaryTermRef href="CDR0000478785" dictionary="Cancer.gov" audience="Patient">specialists</GlossaryTermRef>:</Para><ItemizedList id="_44" Style="bullet"> 
		  <ListItem><GlossaryTermRef href="CDR0000757278" dictionary="Cancer.gov" audience="Patient">Pediatrician</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046370" dictionary="Cancer.gov" audience="Patient">Hematologist</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046290" dictionary="Cancer.gov" audience="Patient">Medical
			 oncologist</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000318823" dictionary="Cancer.gov" audience="Patient">Pediatric surgeon</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046546" dictionary="Cancer.gov" audience="Patient">Radiation
			 oncologist</GlossaryTermRef>.</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000046267" dictionary="Cancer.gov" audience="Patient">Neurologist</GlossaryTermRef>.</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000318818" dictionary="Cancer.gov" audience="Patient">Neuropathologist</GlossaryTermRef>.</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000318819" dictionary="Cancer.gov" audience="Patient">Neuroradiologist</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000318821" dictionary="Cancer.gov" audience="Patient">Pediatric nurse specialist</GlossaryTermRef>.</ListItem><ListItem>
<GlossaryTermRef href="CDR0000044730" dictionary="Cancer.gov" audience="Patient">Social worker</GlossaryTermRef>.</ListItem> 
		  <ListItem><GlossaryTermRef href="CDR0000318825" dictionary="Cancer.gov" audience="Patient">Rehabilitation specialist</GlossaryTermRef>.</ListItem> 
		   
		   
		   
		  <ListItem><GlossaryTermRef href="CDR0000044716" dictionary="Cancer.gov" audience="Patient">Psychologist</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection><SummarySection id="_143"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_144">The treatment of childhood AML and other myeloid malignancies usually has two phases.</KeyPoint><Para id="_145">The treatment of childhood AML is done in phases:</Para><ItemizedList id="_146" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045736" dictionary="Cancer.gov" audience="Patient">Induction therapy</GlossaryTermRef>: This is the first phase of treatment.  The goal is to kill the leukemia <GlossaryTermRef href="CDR0000046476" dictionary="Cancer.gov" audience="Patient">cells</GlossaryTermRef> in the blood and <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef>. This puts the leukemia into <GlossaryTermRef href="CDR0000045867" dictionary="Cancer.gov" audience="Patient">remission</GlossaryTermRef>.</ListItem><ListItem> <GlossaryTermRef href="CDR0000045654" dictionary="Cancer.gov" audience="Patient">Consolidation</GlossaryTermRef>/<GlossaryTermRef href="CDR0000350230" dictionary="Cancer.gov" audience="Patient">intensification therapy</GlossaryTermRef>: This is the second phase of treatment. It begins once the leukemia is in remission. The goal of <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef> is to kill any remaining leukemia cells that are hiding and may not be active but could begin to regrow and cause a <GlossaryTermRef href="CDR0000045866" dictionary="Cancer.gov" audience="Patient">relapse</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_147">Treatment called <GlossaryTermRef href="CDR0000436741" dictionary="Cancer.gov" audience="Patient">central nervous system (CNS) prophylaxis</GlossaryTermRef> therapy may be given during the induction phase of therapy. Because standard <GlossaryTermRef href="CDR0000044664" dictionary="Cancer.gov" audience="Patient">doses</GlossaryTermRef> of <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> may not reach leukemia cells in the <GlossaryTermRef href="CDR0000045643" dictionary="Cancer.gov" audience="Patient">CNS</GlossaryTermRef> (brain and <GlossaryTermRef href="CDR0000340937" dictionary="Cancer.gov" audience="Patient">spinal cord</GlossaryTermRef>), the leukemia cells are able to hide in the CNS. <GlossaryTermRef href="CDR0000046681" dictionary="Cancer.gov" audience="Patient">Intrathecal chemotherapy</GlossaryTermRef> is able to reach leukemia cells in the CNS. It is given to kill the leukemia cells and lessen the chance the leukemia will <GlossaryTermRef href="CDR0000046556" dictionary="Cancer.gov" audience="Patient">recur</GlossaryTermRef> (come back).</Para><Para id="_433">The treatment of childhood APL includes a third phase called <GlossaryTermRef href="CDR0000045768" dictionary="Cancer.gov" audience="Patient">maintenance</GlossaryTermRef>. The goal of maintenance is to kill any remaining leukemia cells that may regrow and cause a relapse. Often the cancer treatments are given in lower doses than those used during the remission induction and consolidation/intensification phases.</Para></SummarySection><SummarySection id="_46"><SectMetaData><SectionType>Standard treatment</SectionType></SectMetaData><KeyPoint id="_47">Seven types of standard treatment may be used for childhood AML and other myeloid malignancies.</KeyPoint><SummarySection id="_48"><KeyPoint id="_49">Chemotherapy </KeyPoint><Para id="_95">Chemotherapy is a cancer treatment that uses <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef> to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injected</GlossaryTermRef> into a <GlossaryTermRef href="CDR0000476471" dictionary="Cancer.gov" audience="Patient">vein</GlossaryTermRef> or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (<GlossaryTermRef href="CDR0000301626" dictionary="Cancer.gov" audience="Patient">systemic chemotherapy</GlossaryTermRef>).  When chemotherapy is placed directly into the <GlossaryTermRef href="CDR0000046483" dictionary="Cancer.gov" audience="Patient">cerebrospinal fluid</GlossaryTermRef> (intrathecal chemotherapy), an <GlossaryTermRef href="CDR0000257523" dictionary="Cancer.gov" audience="Patient">organ</GlossaryTermRef>, or a body <GlossaryTermRef href="CDR0000463703" dictionary="Cancer.gov" audience="Patient">cavity</GlossaryTermRef> such as the <GlossaryTermRef href="CDR0000045070" dictionary="Cancer.gov" audience="Patient">abdomen</GlossaryTermRef>, the drugs mainly affect cancer cells in those areas (<GlossaryTermRef href="CDR0000046559" dictionary="Cancer.gov" audience="Patient">regional chemotherapy</GlossaryTermRef>). <GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">Combination chemotherapy</GlossaryTermRef> is treatment using more than one chemotherapy drug. </Para><Para id="_160">The way the chemotherapy is given depends on the type of cancer being treated. In AML, chemotherapy given by mouth, vein, or into the cerebrospinal fluid is used.</Para><Para id="_245">In AML, the leukemia cells may spread to the brain and/or spinal cord.  Chemotherapy given by mouth or vein to treat AML may not cross the <GlossaryTermRef href="CDR0000046504" dictionary="Cancer.gov" audience="Patient">blood-brain barrier</GlossaryTermRef> to get into the <GlossaryTermRef href="CDR0000044669" dictionary="Cancer.gov" audience="Patient">fluid</GlossaryTermRef> that surrounds the brain and spinal cord. Instead, chemotherapy is injected into the fluid-filled space to kill leukemia cells that may have spread there (intrathecal chemotherapy).<MediaLink ref="CDR0000539773" type="image/jpeg" alt="Intrathecal chemotherapy; drawing shows the cerebrospinal fluid (CSF) in the brain and spinal cord, and an Ommaya reservoir (a dome-shaped container that is placed under the scalp during surgery; it holds the drugs as they flow through a small tube into the brain). Top section shows a syringe and needle injecting anticancer drugs into the Ommaya reservoir. Bottom section shows a syringe and needle injecting anticancer drugs directly into the cerebrospinal fluid in the lower part of the spinal column." language="en" placement="image-center" id="_269"><Caption language="en">Intrathecal chemotherapy. Anticancer drugs are injected into the intrathecal space, which is the space that holds the cerebrospinal fluid (CSF, shown in blue). There are two different ways to do this. One way, shown in the top part of the figure, is to inject the drugs into an Ommaya reservoir (a dome-shaped container that is placed under the scalp during surgery; it holds the drugs as they flow through a small tube into the brain). The other way, shown in the bottom part of the figure, is to inject the drugs directly into the CSF in the lower part of the spinal column, after a small area on the lower back is numbed.  </Caption></MediaLink></Para><Para id="_297">See <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/leukemia#3">Drugs Approved for Acute Myeloid Leukemia</ExternalRef> for more information.</Para></SummarySection><SummarySection id="_124"><KeyPoint id="_125">Radiation therapy</KeyPoint><Para id="_126"><GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">Radiation therapy</GlossaryTermRef> is a cancer treatment that uses high-energy <GlossaryTermRef href="CDR0000045944" dictionary="Cancer.gov" audience="Patient">x-rays</GlossaryTermRef> or other types of <GlossaryTermRef href="CDR0000045072" dictionary="Cancer.gov" audience="Patient">radiation</GlossaryTermRef> to kill cancer cells or keep them from growing. <GlossaryTermRef href="CDR0000046686" dictionary="Cancer.gov" audience="Patient">External radiation therapy</GlossaryTermRef> uses a machine outside the body to send radiation toward the area of the body with cancer. </Para><Para id="_360">In childhood AML, external radiation therapy may be used to treat a <GlossaryTermRef href="CDR0000806037" dictionary="Cancer.gov" audience="Patient">myeloid sarcoma</GlossaryTermRef> that does not <GlossaryTermRef href="CDR0000044085" dictionary="Cancer.gov" audience="Patient">respond</GlossaryTermRef> to chemotherapy.</Para></SummarySection><SummarySection id="_148"><KeyPoint id="_149">Stem cell transplant</KeyPoint><Para id="_432">Chemotherapy is given to kill cancer cells or other <GlossaryTermRef href="CDR0000044636" dictionary="Cancer.gov" audience="Patient">abnormal</GlossaryTermRef> blood cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">Stem cell transplant</GlossaryTermRef> is a treatment to replace the blood-forming cells. <GlossaryTermRef href="CDR0000046598" dictionary="Cancer.gov" audience="Patient">Stem cells</GlossaryTermRef> (immature blood cells) are removed from the blood or bone marrow of the patient or a <GlossaryTermRef href="CDR0000643010" dictionary="Cancer.gov" audience="Patient">donor</GlossaryTermRef> and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given to the patient through an <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusion</GlossaryTermRef>. These reinfused stem cells grow into (and restore) the body's blood cells.</Para><MediaLink ref="CDR0000765030" type="image/jpeg" alt="Donor stem cell transplant; (Panel 1): Drawing of stem cells being collected from a donor's bloodstream using an apheresis machine. Blood is removed from a vein in the donor's arm and flows through the machine where the stem cells are removed. The rest of the blood is then returned to the donor through a vein in their other arm. (Panel 2): Drawing of a health care provider giving a patient an infusion of chemotherapy through a catheter in the patient's chest. The chemotherapy is given to kill cancer cells and prepare the patient's body for the donor stem cells. (Panel 3): Drawing of a patient receiving an infusion of the donor stem cells through a catheter in the chest." language="en" placement="image-center" id="_357"><Caption language="en">Donor stem cell transplant. (Step 1): Four to five days before donor stem cell collection, the donor receives a medicine to increase the number of stem cells circulating through their bloodstream (not shown). The blood-forming stem cells are then collected from the donor through a large vein in their arm. The blood flows through an apheresis machine that removes the stem cells. The rest of the blood is returned to the donor through a vein in their other arm. (Step 2): The patient receives chemotherapy to kill cancer cells and prepare their body for the donor stem cells. The patient may also receive radiation therapy (not shown). (Step 3): The patient receives an infusion of the donor stem cells.</Caption></MediaLink></SummarySection><SummarySection id="_335"><KeyPoint id="_359">Targeted therapy</KeyPoint><Para id="_336"><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do. Types of targeted therapy include the following:</Para><ItemizedList id="_337" Style="bullet" Compact="No"><ListItem><Strong><GlossaryTermRef href="CDR0000044833" dictionary="Cancer.gov" audience="Patient">Tyrosine kinase inhibitor</GlossaryTermRef> therapy:</Strong> This treatment blocks the <GlossaryTermRef href="CDR0000046081" dictionary="Cancer.gov" audience="Patient">enzyme</GlossaryTermRef>, tyrosine kinase, that causes stem cells to become more <GlossaryTermRef href="CDR0000045993" dictionary="Cancer.gov" audience="Patient">white blood cells</GlossaryTermRef> (<GlossaryTermRef href="CDR0000046503" dictionary="Cancer.gov" audience="Patient">blasts</GlossaryTermRef>) than the body needs. Tyrosine kinase inhibitors may be used with chemotherapy drugs as <GlossaryTermRef href="CDR0000045587" dictionary="Cancer.gov" audience="Patient">adjuvant therapy</GlossaryTermRef> (treatment given after the initial treatment, to lower the risk that the cancer will come back).

 <ItemizedList id="_338" Style="dash" Compact="No">
     <ListItem><GlossaryTermRef href="CDR0000044893" dictionary="Cancer.gov" audience="Patient">Imatinib</GlossaryTermRef>, <GlossaryTermRef href="CDR0000484435" dictionary="Cancer.gov" audience="Patient">dasatinib</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000575396" dictionary="Cancer.gov" audience="Patient">nilotinib</GlossaryTermRef> are used to treat childhood chronic myelogenous leukemia. </ListItem><ListItem><GlossaryTermRef href="CDR0000509041" dictionary="Cancer.gov" audience="Patient">Sorafenib</GlossaryTermRef>, <GlossaryTermRef href="CDR0000513012" dictionary="Cancer.gov" audience="Patient">midostaurin</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000795814" dictionary="Cancer.gov" audience="Patient">gilteritinib</GlossaryTermRef>, which target a <GlossaryTermRef href="CDR0000044133" dictionary="Cancer.gov" audience="Patient">mutated</GlossaryTermRef> (changed) form of a <GlossaryTermRef href="CDR0000045693" dictionary="Cancer.gov" audience="Patient">gene</GlossaryTermRef> called <GeneName><GlossaryTermRef href="CDR0000789010" dictionary="Cancer.gov" audience="Patient">FLT3</GlossaryTermRef></GeneName>, are being studied to treat childhood AML.</ListItem><ListItem> <GlossaryTermRef href="CDR0000750072" dictionary="Cancer.gov" audience="Patient">Trametinib</GlossaryTermRef> is being studied in children with <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurrent</GlossaryTermRef> or <GlossaryTermRef href="CDR0000350245" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> juvenile myelomonocytic leukemia.</ListItem></ItemizedList></ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">Monoclonal antibodies</GlossaryTermRef>:</Strong> Monoclonal antibodies are <GlossaryTermRef href="CDR0000046356" dictionary="Cancer.gov" audience="Patient">immune system</GlossaryTermRef> <GlossaryTermRef href="CDR0000046092" dictionary="Cancer.gov" audience="Patient">proteins</GlossaryTermRef> made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, <GlossaryTermRef href="CDR0000046622" dictionary="Cancer.gov" audience="Patient">toxins</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000046550" dictionary="Cancer.gov" audience="Patient">radioactive</GlossaryTermRef> material directly to cancer cells. <ItemizedList id="_340" Style="dash"><ListItem><GlossaryTermRef href="CDR0000045569" dictionary="Cancer.gov" audience="Patient">Gemtuzumab ozogamicin</GlossaryTermRef> is a type of monoclonal antibody that is attached to a chemotherapy drug. It is used in the treatment of AML.</ListItem></ItemizedList> </ListItem></ItemizedList><EmbeddedVideo id="_319" ref="CDR0000801837" hosting="youtube" unique_id="dxnjAc-rqz8" language="en" audience="Patients" template="Video75NoTitle"><VideoTitle>monoclonal antibodies: how monoclonal antibodies treat cancer</VideoTitle><Caption language="en">How do  monoclonal antibodies work to treat cancer? This video shows how monoclonal antibodies, such as trastuzumab, pembrolizumab, and rituximab, block molecules cancer cells need to grow, flag cancer cells for destruction by the body’s immune system, or deliver harmful substances to cancer cells. </Caption></EmbeddedVideo><Para id="_301">See <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/leukemia">Drugs Approved for Leukemia</ExternalRef> for more information.</Para></SummarySection><SummarySection id="_151"><KeyPoint id="_152">Other drug therapy</KeyPoint><Para id="_308"><GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">Lenalidomide</GlossaryTermRef> may be used to lessen the need for <GlossaryTermRef href="CDR0000046001" dictionary="Cancer.gov" audience="Patient">transfusions</GlossaryTermRef> in patients who have   <GlossaryTermRef href="CDR0000045266" dictionary="Cancer.gov" audience="Patient">myelodysplastic syndromes</GlossaryTermRef> caused by a specific <GlossaryTermRef href="CDR0000046470" dictionary="Cancer.gov" audience="Patient">chromosome</GlossaryTermRef> change.</Para><Para id="_153"><GlossaryTermRef href="CDR0000046018" dictionary="Cancer.gov" audience="Patient">Arsenic trioxide</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045351" dictionary="Cancer.gov" audience="Patient">tretinoin</GlossaryTermRef> are drugs that kill certain types of leukemia cells, stop the leukemia cells from dividing, or help the leukemia cells mature into white blood cells. These drugs are used in the treatment of acute promyelocytic leukemia.</Para><Para id="_299">See <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/leukemia#3">Drugs Approved for Acute Myeloid Leukemia</ExternalRef> for more information.</Para></SummarySection><SummarySection id="_161"><KeyPoint id="_162">Watchful waiting</KeyPoint><Para id="_163"><GlossaryTermRef href="CDR0000045942" dictionary="Cancer.gov" audience="Patient">Watchful waiting</GlossaryTermRef> is closely <GlossaryTermRef href="CDR0000454803" dictionary="Cancer.gov" audience="Patient">monitoring</GlossaryTermRef> a patient’s <GlossaryTermRef href="CDR0000651193" dictionary="Cancer.gov" audience="Patient">condition</GlossaryTermRef> without giving any treatment until <GlossaryTermRef href="CDR0000750109" dictionary="Cancer.gov" audience="Patient">signs</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045022" dictionary="Cancer.gov" audience="Patient">symptoms</GlossaryTermRef> appear or change.  It is sometimes used to treat transient abnormal myelopoiesis (TAM).</Para></SummarySection><SummarySection id="_246"><KeyPoint id="_247">Supportive care</KeyPoint><Para id="_248"><GlossaryTermRef href="CDR0000046609" dictionary="Cancer.gov" audience="Patient">Supportive care</GlossaryTermRef> is given to lessen the problems caused by the disease or its treatment. All patients with leukemia receive supportive care treatments. Supportive care may include the following:</Para><ItemizedList id="_249" Style="bullet"><ListItem>Transfusion therapy:  A way of giving <GlossaryTermRef href="CDR0000046124" dictionary="Cancer.gov" audience="Patient">red blood cells</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045840" dictionary="Cancer.gov" audience="Patient">platelets</GlossaryTermRef> to replace blood cells destroyed by disease or cancer treatment.

The blood may be <GlossaryTermRef href="CDR0000643010" dictionary="Cancer.gov" audience="Patient">donated</GlossaryTermRef> from another person or it may have been taken from the patient earlier and stored until needed.</ListItem><ListItem>Antifungal agents: Drugs, such as <GlossaryTermRef href="CDR0000045000" dictionary="Cancer.gov" audience="Patient">Caspofungin</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045320" dictionary="Cancer.gov" audience="Patient">fluconazole</GlossaryTermRef>, used to prevent or treat <GlossaryTermRef href="CDR0000045364" dictionary="Cancer.gov" audience="Patient">infections</GlossaryTermRef> caused by a <GlossaryTermRef href="CDR0000044571" dictionary="Cancer.gov" audience="Patient">fungus</GlossaryTermRef> (a type of <GlossaryTermRef href="CDR0000044059" dictionary="Cancer.gov" audience="Patient">microorganism</GlossaryTermRef>).   This is important in the care  of patients with AML.</ListItem><ListItem><GlossaryTermRef href="CDR0000651195" dictionary="Cancer.gov" audience="Patient">Drug therapy</GlossaryTermRef>, such as <GlossaryTermRef href="CDR0000045967" dictionary="Cancer.gov" audience="Patient">antibiotics</GlossaryTermRef>.</ListItem><ListItem>Leukapheresis: A procedure in which a special machine is used to remove white blood cells from the blood. Blood is taken from the patient and put through a blood cell separator where the white blood cells are removed. The rest of the blood is then returned to the patient's bloodstream. Leukapheresis is used to treat patients with very high white blood cell counts.</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_51"><SectMetaData><SectionType>Treatment in clinical trials</SectionType></SectMetaData><KeyPoint id="_52"> New types of treatment are being tested in clinical trials.
		  </KeyPoint><Para id="_259">This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI website</ExternalRef>.</Para></SummarySection><SummarySection id="_275"><KeyPoint id="_276">Treatment for childhood acute myeloid leukemia and other myeloid malignancies may cause side effects.</KeyPoint><Para id="_275_md_76">To learn more about <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> that begin during treatment for cancer, visit <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/side-effects">Side Effects</ExternalRef>.</Para><Para id="_277">Regular <GlossaryTermRef href="CDR0000044671" dictionary="Cancer.gov" audience="Patient">follow-up</GlossaryTermRef> exams are very important. Side effects from cancer treatment that begin after treatment and continue for months or years are called <GlossaryTermRef href="CDR0000390292" dictionary="Cancer.gov" audience="Patient">late effects</GlossaryTermRef>. Late effects of cancer treatment may include the following:</Para><ItemizedList id="_278" Style="bullet">
    <ListItem>Physical problems that affect the following:<ItemizedList id="_434" Style="bullet"><ListItem>Heart, <GlossaryTermRef href="CDR0000270740" dictionary="Cancer.gov" audience="Patient">lung</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000458098" dictionary="Cancer.gov" audience="Patient">endocrine</GlossaryTermRef> function.</ListItem><ListItem>Bone development.</ListItem><ListItem><GlossaryTermRef href="CDR0000046399" dictionary="Cancer.gov" audience="Patient">Fertility</GlossaryTermRef> (ability to have children).</ListItem><ListItem>Energy level.</ListItem></ItemizedList></ListItem>
    <ListItem>Changes in mood, feelings, thinking, learning, or memory.</ListItem>
    <ListItem><GlossaryTermRef href="CDR0000046658" dictionary="Cancer.gov" audience="Patient">Second cancers</GlossaryTermRef> (new types of cancer), such as <GlossaryTermRef href="CDR0000444971" dictionary="Cancer.gov" audience="Patient">breast cancer</GlossaryTermRef>.</ListItem>
   </ItemizedList><Para id="_279">Some late effects may be treated or controlled. It is important that parents of children who are treated for AML or other <GlossaryTermRef href="CDR0000270735" dictionary="Cancer.gov" audience="Patient">blood</GlossaryTermRef> diseases talk with their child's doctors about the effects cancer treatment can have on their child. (See the PDQ summary on <SummaryRef href="CDR0000373791" url="/types/childhood-cancers/late-effects-pdq">Late Effects of Treatment for Childhood Cancer</SummaryRef> for more information).</Para></SummarySection><SummarySection id="_260"><KeyPoint id="_261">Patients may want to think about taking part in a clinical trial.</KeyPoint><Para id="_260_md_23">For some patients, taking part in a <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer  treatments are safe and effective or better than the <GlossaryTermRef href="CDR0000044930" dictionary="Cancer.gov" audience="Patient">standard treatment</GlossaryTermRef>.</Para><Para id="_260_md_24">Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first  to receive a new treatment.</Para><Para id="_260_md_25">Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.</Para></SummarySection><SummarySection id="_262"><KeyPoint id="_263">Patients can enter clinical trials before, during, or after starting their cancer treatment.</KeyPoint><Para id="_262_md_29">Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the <GlossaryTermRef href="CDR0000046580" dictionary="Cancer.gov" audience="Patient">side effects</GlossaryTermRef> of cancer treatment.</Para><Para id="_262_md_30">Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search">clinical trials search</ExternalRef> webpage. Clinical trials supported by other organizations can be found on the <ExternalRef xref="https://clinicaltrials.gov/">ClinicalTrials.gov</ExternalRef> website.</Para></SummarySection><SummarySection id="_264"><KeyPoint id="_265">Follow-up tests may be needed.</KeyPoint><Para id="_264_md_55">As your child goes through treatment, they will have follow-up tests or check-ups. Some tests that were done to <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnose</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045885" dictionary="Cancer.gov" audience="Patient">stage</GlossaryTermRef> the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.</Para><Para id="_264_md_56">Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the cancer has recurred (come back). </Para></SummarySection></SummarySection><SummarySection id="_97"><SectMetaData><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Childhood Acute Myeloid Leukemia</Title><Para id="_424">For information about the treatments listed below, see the <SummaryRef href="CDR0000258000#_46" url="/types/leukemia/patient/child-aml-treatment-pdq">Treatment Option Overview</SummaryRef>  section.</Para><Para id="_382">Treatment of newly <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosed</GlossaryTermRef> childhood <GlossaryTermRef href="CDR0000046347" dictionary="Cancer.gov" audience="Patient">acute myeloid leukemia</GlossaryTermRef> (AML) during the <GlossaryTermRef href="CDR0000045736" dictionary="Cancer.gov" audience="Patient">induction</GlossaryTermRef> phase may include the following:</Para><ItemizedList id="_383" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">Combination chemotherapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000436741" dictionary="Cancer.gov" audience="Patient">Central nervous system prophylaxis</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef> with <GlossaryTermRef href="CDR0000046681" dictionary="Cancer.gov" audience="Patient">intrathecal chemotherapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> with a <GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">monoclonal antibody</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045569" dictionary="Cancer.gov" audience="Patient">gemtuzumab ozogamicin</GlossaryTermRef>).</ListItem><ListItem>A <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> of targeted therapy (<GlossaryTermRef href="CDR0000509041" dictionary="Cancer.gov" audience="Patient">sorafenib</GlossaryTermRef>).</ListItem><ListItem>A clinical trial of <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> and targeted therapy (<GlossaryTermRef href="CDR0000795814" dictionary="Cancer.gov" audience="Patient">gilteritinib</GlossaryTermRef>). </ListItem><ListItem><GlossaryTermRef href="CDR0000046609" dictionary="Cancer.gov" audience="Patient">Supportive care</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_384">
Treatment of childhood AML during the <GlossaryTermRef href="CDR0000045867" dictionary="Cancer.gov" audience="Patient">remission</GlossaryTermRef> phase (<GlossaryTermRef href="CDR0000045654" dictionary="Cancer.gov" audience="Patient">consolidation</GlossaryTermRef>/<GlossaryTermRef href="CDR0000350230" dictionary="Cancer.gov" audience="Patient">intensification therapy</GlossaryTermRef>) depends on the subtype of AML and may include the following:

</Para><ItemizedList id="_385" Style="bullet"><ListItem>Combination chemotherapy.</ListItem><ListItem><GlossaryTermRef href="CDR0000346522" dictionary="Cancer.gov" audience="Patient">High-dose chemotherapy</GlossaryTermRef> followed by <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient"/> using <GlossaryTermRef href="CDR0000765906" dictionary="Cancer.gov" audience="Patient">blood stem cells</GlossaryTermRef> from a <GlossaryTermRef href="CDR0000643010" dictionary="Cancer.gov" audience="Patient">donor</GlossaryTermRef>.
</ListItem><ListItem>Targeted therapy (such as  <GeneName><GlossaryTermRef href="CDR0000789010" dictionary="Cancer.gov" audience="Patient">FLT3</GlossaryTermRef></GeneName> inhibitors).</ListItem></ItemizedList><Para id="_386">Treatment of <GlossaryTermRef href="CDR0000045863" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> childhood AML may
		  include the following:</Para><ItemizedList id="_387" Style="bullet"><ListItem>Chemotherapy.</ListItem><ListItem>Targeted therapy with a monoclonal antibody (gemtuzumab ozogamicin).</ListItem><ListItem><GlossaryTermRef href="CDR0000044971" dictionary="Cancer.gov" audience="Patient">Radiation therapy</GlossaryTermRef> to treat a <GlossaryTermRef href="CDR0000806037" dictionary="Cancer.gov" audience="Patient">myeloid sarcoma</GlossaryTermRef> that does not completely respond to chemotherapy.</ListItem></ItemizedList><Para id="_388"> Treatment of <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurrent</GlossaryTermRef> childhood AML may
		  include the following:</Para><ItemizedList id="_389" Style="bullet"><ListItem>Combination chemotherapy.</ListItem><ListItem>Targeted therapy with a monoclonal antibody (gemtuzumab ozogamicin).</ListItem><ListItem>Radiation therapy to treat locally recurring myeloid sarcoma.</ListItem><ListItem>A clinical trial of targeted therapy (<GlossaryTermRef href="CDR0000513012" dictionary="Cancer.gov" audience="Patient">midostaurin</GlossaryTermRef>, sorafenib, or gilteritinib).</ListItem><ListItem>Combination chemotherapy and stem cell transplant, for patients who have had a second complete remission.</ListItem> 
		  <ListItem>A second stem cell transplant, for patients whose disease came back after the first stem cell transplant.</ListItem></ItemizedList></SummarySection><SummarySection id="_390"><Title>Treatment of Transient Abnormal Myelopoiesis or Children with Down Syndrome and AML</Title><Para id="_425">For information about the treatments listed below, see the <SummaryRef href="CDR0000258000#_46" url="/types/leukemia/patient/child-aml-treatment-pdq">Treatment Option Overview</SummaryRef>  section.</Para><Para id="_391"><GlossaryTermRef href="CDR0000792763" dictionary="Cancer.gov" audience="Patient">Transient abnormal myelopoiesis</GlossaryTermRef> (TAM) usually goes away on its own. For newly <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosed</GlossaryTermRef> TAM that does not go away on its own or causes other health problems, treatment may include the following:</Para><ItemizedList id="_392" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000046609" dictionary="Cancer.gov" audience="Patient">Supportive care</GlossaryTermRef>, including <GlossaryTermRef href="CDR0000046001" dictionary="Cancer.gov" audience="Patient">transfusion</GlossaryTermRef> therapy or <GlossaryTermRef href="CDR0000045252" dictionary="Cancer.gov" audience="Patient">leukapheresis</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">Chemotherapy</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_393">Treatment of newly diagnosed <GlossaryTermRef href="CDR0000046347" dictionary="Cancer.gov" audience="Patient">acute myeloid leukemia</GlossaryTermRef> (AML) in children aged 4 years or younger who have <GlossaryTermRef href="CDR0000045488" dictionary="Cancer.gov" audience="Patient">Down syndrome</GlossaryTermRef> may include the following:</Para><ItemizedList id="_394" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">Combination chemotherapy</GlossaryTermRef> plus  <GlossaryTermRef href="CDR0000436741" dictionary="Cancer.gov" audience="Patient">central nervous system prophylaxis</GlossaryTermRef> therapy with <GlossaryTermRef href="CDR0000046681" dictionary="Cancer.gov" audience="Patient">intrathecal chemotherapy</GlossaryTermRef>.</ListItem><ListItem>A <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> of a new chemotherapy <GlossaryTermRef href="CDR0000045864" dictionary="Cancer.gov" audience="Patient">regimen</GlossaryTermRef> that depends on how the child <GlossaryTermRef href="CDR0000044085" dictionary="Cancer.gov" audience="Patient">responds</GlossaryTermRef> to initial chemotherapy.</ListItem></ItemizedList><Para id="_395">Treatment of newly diagnosed AML in children older than 4 years who have Down syndrome may be the same as treatment for children without Down syndrome.</Para></SummarySection><SummarySection id="_396"><Title>Treatment of Childhood Acute Promyelocytic Leukemia</Title><Para id="_426">For information about the treatments listed below, see the <SummaryRef href="CDR0000258000#_46" url="/types/leukemia/patient/child-aml-treatment-pdq">Treatment Option Overview</SummaryRef>  section.</Para><Para id="_397">Treatment of newly <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosed</GlossaryTermRef> childhood <GlossaryTermRef href="CDR0000444957" dictionary="Cancer.gov" audience="Patient">acute promyelocytic leukemia</GlossaryTermRef> (APL) may include the following:</Para><ItemizedList id="_398" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045351" dictionary="Cancer.gov" audience="Patient">Tretinoin</GlossaryTermRef> with <GlossaryTermRef href="CDR0000046018" dictionary="Cancer.gov" audience="Patient">arsenic trioxide</GlossaryTermRef>. </ListItem><ListItem>Tretinoin plus <GlossaryTermRef href="CDR0000045214" dictionary="Cancer.gov" audience="Patient">chemotherapy</GlossaryTermRef> with or without arsenic trioxide.</ListItem><ListItem><GlossaryTermRef href="CDR0000046609" dictionary="Cancer.gov" audience="Patient">Supportive care</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_399">Treatment of childhood APL during the <GlossaryTermRef href="CDR0000045867" dictionary="Cancer.gov" audience="Patient">remission</GlossaryTermRef> phase (<GlossaryTermRef href="CDR0000045654" dictionary="Cancer.gov" audience="Patient">consolidation</GlossaryTermRef>/<GlossaryTermRef href="CDR0000350230" dictionary="Cancer.gov" audience="Patient">intensification therapy</GlossaryTermRef>) may include the following:</Para><ItemizedList id="_400" Style="bullet"><ListItem>Tretinoin with arsenic trioxide.</ListItem><ListItem>Tretinoin plus chemotherapy with or without arsenic trioxide.</ListItem></ItemizedList><Para id="_435">Treatment of childhood APL during the remission phase (<GlossaryTermRef href="CDR0000045768" dictionary="Cancer.gov" audience="Patient">maintenance therapy</GlossaryTermRef>) may include the following:</Para><ItemizedList id="_436" Style="bullet"><ListItem>Tretinoin with <GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">combination chemotherapy</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_401">Treatment of <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurrent</GlossaryTermRef> childhood APL may include the following:</Para><ItemizedList id="_402" Style="bullet"><ListItem>Arsenic trioxide therapy with or without tretinoin.</ListItem><ListItem><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> with a <GlossaryTermRef href="CDR0000046066" dictionary="Cancer.gov" audience="Patient">monoclonal antibody</GlossaryTermRef> (<GlossaryTermRef href="CDR0000045569" dictionary="Cancer.gov" audience="Patient">gemtuzumab ozogamicin</GlossaryTermRef>).</ListItem><ListItem><GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">Stem cell transplant</GlossaryTermRef> using <GlossaryTermRef href="CDR0000765906" dictionary="Cancer.gov" audience="Patient">blood stem cells</GlossaryTermRef> from the patient or a <GlossaryTermRef href="CDR0000643010" dictionary="Cancer.gov" audience="Patient">donor</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection><SummarySection id="_405"><Title>Treatment of Juvenile Myelomonocytic Leukemia</Title><Para id="_427">For information about the treatments listed below, see the <SummaryRef href="CDR0000258000#_46" url="/types/leukemia/patient/child-aml-treatment-pdq">Treatment Option Overview</SummaryRef>  section.</Para><Para id="_406">Treatment of newly <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosed</GlossaryTermRef> <GlossaryTermRef href="CDR0000045048" dictionary="Cancer.gov" audience="Patient">juvenile myelomonocytic leukemia</GlossaryTermRef> (JMML) may include the following:</Para><ItemizedList id="_407" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000045650" dictionary="Cancer.gov" audience="Patient">Combination chemotherapy</GlossaryTermRef> followed by <GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">stem cell transplant</GlossaryTermRef>.</ListItem></ItemizedList><Para id="_430">Treatment of <GlossaryTermRef href="CDR0000045863" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurrent</GlossaryTermRef> childhood JMML may include the following:</Para><ItemizedList id="_431" Style="bullet"><ListItem>A second stem cell transplant, for patients whose disease came back after the first stem cell transplant.</ListItem><ListItem>A <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> of <GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">targeted therapy</GlossaryTermRef> with a <GlossaryTermRef href="CDR0000044833" dictionary="Cancer.gov" audience="Patient">tyrosine kinase inhibitor</GlossaryTermRef> (<GlossaryTermRef href="CDR0000750072" dictionary="Cancer.gov" audience="Patient">trametinib</GlossaryTermRef>).</ListItem></ItemizedList></SummarySection><SummarySection id="_408"><Title>Treatment of Childhood Chronic Myelogenous Leukemia</Title><Para id="_428">For information about the treatments listed below, see the <SummaryRef href="CDR0000258000#_46" url="/types/leukemia/patient/child-aml-treatment-pdq">Treatment Option Overview</SummaryRef>  section.</Para><Para id="_409">Treatment of newly <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosed</GlossaryTermRef> <GlossaryTermRef href="CDR0000044901" dictionary="Cancer.gov" audience="Patient">chronic myelogenous leukemia</GlossaryTermRef> (CML) may include the following:</Para><ItemizedList id="_410" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000270742" dictionary="Cancer.gov" audience="Patient">Targeted therapy</GlossaryTermRef> with a <GlossaryTermRef href="CDR0000044833" dictionary="Cancer.gov" audience="Patient">tyrosine kinase inhibitor</GlossaryTermRef> (<GlossaryTermRef href="CDR0000044893" dictionary="Cancer.gov" audience="Patient">imatinib</GlossaryTermRef>, <GlossaryTermRef href="CDR0000484435" dictionary="Cancer.gov" audience="Patient">dasatinib</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000575396" dictionary="Cancer.gov" audience="Patient">nilotinib</GlossaryTermRef>).</ListItem><ListItem>A <GlossaryTermRef href="CDR0000045961" dictionary="Cancer.gov" audience="Patient">clinical trial</GlossaryTermRef> to study the rate of CML <GlossaryTermRef href="CDR0000045861" dictionary="Cancer.gov" audience="Patient">recurrence</GlossaryTermRef> after stopping tyrosine kinase inhibitor therapy, and the ability to achieve <GlossaryTermRef href="CDR0000045867" dictionary="Cancer.gov" audience="Patient">remission</GlossaryTermRef> again if CML recurs in children with CML who are in remission for at least 2 years after receiving treatment with the same tyrosine kinase inhibitor for at least 3 years. </ListItem></ItemizedList><Para id="_411">Treatment of <GlossaryTermRef href="CDR0000045863" dictionary="Cancer.gov" audience="Patient">refractory</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045862" dictionary="Cancer.gov" audience="Patient">recurrent</GlossaryTermRef> childhood CML may include the following:</Para><ItemizedList id="_412" Style="bullet"><ListItem>Targeted therapy with a tyrosine kinase inhibitor (dasatinib or nilotinib).</ListItem><ListItem><GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">Stem cell transplant</GlossaryTermRef> using <GlossaryTermRef href="CDR0000765906" dictionary="Cancer.gov" audience="Patient">blood stem cells</GlossaryTermRef> from a <GlossaryTermRef href="CDR0000643010" dictionary="Cancer.gov" audience="Patient">donor</GlossaryTermRef>.</ListItem></ItemizedList></SummarySection><SummarySection id="_403"><Title>Treatment of Childhood Myelodysplastic Syndromes</Title><Para id="_429">For information about the treatments listed below, see the <SummaryRef href="CDR0000258000#_46" url="/types/leukemia/patient/child-aml-treatment-pdq">Treatment Option Overview</SummaryRef>  section.</Para><Para id="_404">Treatment of newly <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosed</GlossaryTermRef> childhood <GlossaryTermRef href="CDR0000045266" dictionary="Cancer.gov" audience="Patient">myelodysplastic syndromes</GlossaryTermRef> (MDS) may include the following:</Para><ItemizedList id="_413" Style="bullet"><ListItem><GlossaryTermRef href="CDR0000046695" dictionary="Cancer.gov" audience="Patient">Stem cell transplant</GlossaryTermRef> using <GlossaryTermRef href="CDR0000765906" dictionary="Cancer.gov" audience="Patient">blood stem cells</GlossaryTermRef> from a <GlossaryTermRef href="CDR0000643010" dictionary="Cancer.gov" audience="Patient">donor</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000046609" dictionary="Cancer.gov" audience="Patient">Supportive care</GlossaryTermRef>, including <GlossaryTermRef href="CDR0000046001" dictionary="Cancer.gov" audience="Patient">transfusion</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045967" dictionary="Cancer.gov" audience="Patient">antibiotics</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000045111" dictionary="Cancer.gov" audience="Patient">Steroid therapy</GlossaryTermRef>.</ListItem><ListItem><GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">Lenalidomide</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef>, for patients with certain <GlossaryTermRef href="CDR0000045693" dictionary="Cancer.gov" audience="Patient">gene</GlossaryTermRef> changes.</ListItem></ItemizedList><Para id="_414">If the MDS becomes <GlossaryTermRef href="CDR0000046347" dictionary="Cancer.gov" audience="Patient">acute myeloid leukemia</GlossaryTermRef> (AML), treatment will be the same as treatment for newly <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosed</GlossaryTermRef> AML.</Para></SummarySection><SummarySection id="_253"><Title>To Learn More About Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies</Title><Para id="_254">For more information from the <GlossaryTermRef href="CDR0000044266" dictionary="Cancer.gov" audience="Patient">National Cancer Institute</GlossaryTermRef> about  childhood acute myeloid leukemia and other myeloid malignancies, see the following:</Para><ItemizedList id="_300" Style="bullet"><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/leukemia#3">Drugs Approved for Acute Myeloid Leukemia</ExternalRef></ListItem><ListItem> <ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/drugs/myeloproliferative-neoplasms#1">Drugs Approved for Myeloproliferative Neoplasms</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant/stem-cell-fact-sheet">Blood-Forming Stem Cell Transplants</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Cancer Therapies</ExternalRef></ListItem></ItemizedList><Para id="_253_md_44">For more childhood cancer information and other general cancer resources, visit:</Para><ItemizedList id="_253_md_45" Style="bullet"><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer">About Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/types/childhood-cancers">Childhood Cancers</ExternalRef></ListItem><ListItem><ExternalRef xref="http://www.curesearch.org/">CureSearch for Children's Cancer</ExternalRef>
</ListItem><ListItem><SummaryRef href="CDR0000373791" url="/types/childhood-cancers/late-effects-pdq">Late Effects of Treatment for Childhood Cancer</SummaryRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/types/aya">Adolescents and Young Adults with Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/publications/patient-education/guide-for-parents">Children with Cancer: A Guide for Parents</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet">Cancer in Children and Adolescents</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/diagnosis-staging/staging">Cancer Staging</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/coping">Coping with Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://www.cancer.gov/about-cancer/coping/questions">Questions to Ask Your Doctor about Cancer</ExternalRef></ListItem><ListItem><ExternalRef xref="https://cancercontrol.cancer.gov/ocs/resources/survivors.html">For Survivors, Caregivers, and Advocates</ExternalRef></ListItem></ItemizedList></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>About PDQ</Title><Para id="_AboutThis_3">Physician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in <ExternalRef xref="https://www.cancer.gov/espanol/publicaciones/pdq">Spanish</ExternalRef>.</Para><Para id="_AboutThis_4">PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government’s center of biomedical research.  The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.</Para></SummarySection><SummarySection id="_AboutThis_5"><Title>Purpose of This Summary</Title><Para id="_AboutThis_6">This PDQ cancer information summary has current information about the treatment of childhood acute myeloid leukemia and other myeloid malignancies.  It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.</Para></SummarySection><SummarySection id="_AboutThis_7"><Title>Reviewers and Updates</Title><Para id="_AboutThis_8">Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Updated") is the date of the most recent change.
</Para><Para id="_AboutThis_9">The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</ExternalRef>.
</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Clinical Trial Information</Title><Para id="_AboutThis_11">A clinical trial is a study to answer a scientific question, such as whether one treatment is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. During treatment clinical trials, information is collected about the effects of a new treatment and how well it works. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
</Para><Para id="_AboutThis_12">Clinical trials can be found online at <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">NCI's website</ExternalRef>. For more information, call the <ExternalRef xref="https://www.cancer.gov/contact/contact-center">Cancer Information Service</ExternalRef> (CIS), NCI's contact center, at 1-800-4-CANCER (1-800-422-6237).
</Para></SummarySection><SummarySection id="_AboutThis_13"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_14">PDQ is a registered trademark. The content of PDQ documents can be used freely as text. It cannot be identified as an NCI PDQ cancer information summary unless the whole summary is shown and it is updated regularly. However, a user would be allowed to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks in the following way: [include excerpt from the summary].”
</Para><Para id="_AboutThis_15">The best way to cite this PDQ summary is:</Para><Para id="_AboutThis_21">PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/leukemia/patient/child-aml-treatment-pdq">https://www.cancer.gov/types/leukemia/patient/child-aml-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389303]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use in the PDQ summaries only. If you want to use an image from a PDQ summary and you are not using the whole summary, you must get permission from the owner. It cannot be given by the National Cancer Institute. Information about using the images in this summary, along with many other images related to cancer can be found in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>. Visuals Online is a collection of more than 3,000 scientific images.
</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">The information in these summaries should not be used to make decisions about insurance reimbursement. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_19"><Title>Contact Us</Title><Para id="_AboutThis_20">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">E-mail Us</ExternalRef>.</Para></SummarySection></SummarySection><PatientVersionOf ref="CDR0000062896"/><DateLastModified>2024-06-05</DateLastModified></Summary>
